Ortho Clinical Diagnostics Archives - Medical Design Sourcing

Quidel, Ortho Clinical Diagnostics combine to form in vitro diagnostics company

Quidel (Nasdaq:QDEL) announced today that it completed its $6 billion acquisition of Ortho Clinical Diagnostics (Nasdaq:OCDX).

In December 2021, San Diego-based Quidel and Ortho Clinical Diagnostics came to an agreement under which the former would acquire the latter for $24.68 per share of common stock, using a combination of cash and newly issued shares in the combined company, representing a 25% premium on Ortho’s closing price on Dec. 22, 2021, and an equity value of about $6 billion.

Under the terms, former Ortho shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share. Former Quidel stockholders received one share of QuidelOrtho common stock for each share of Quidel common stock, according to a news release.

Under the terms of the agreement governing the transaction, former Ortho shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share. Former …

Quidel to acquire Ortho Clinical Diagnostics for $6B

Quidel (NSDQ:QDEL) announced today that it acquired Ortho Clinical Diagnostics (NSDQ:OCDX) for approximately $6 billion.

Under a definitive agreement,Quidel will acquire Ortho for $24.68 per share of common stock, using a combination of cash and newly issued shares in the combined company, representing a 25% premium on Ortho’s closing price on Dec. 22, 2021, and an equity value of about $6 billion.

The transaction aims to unite technologies and platforms to offer expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening and point-of-care diagnostic offerings.

According to a news release, the companies expect the transaction to close during the first half of the 2022 fiscal year, subject to customary closing conditions.

“The combination with Ortho will help solidify Quidel as a leader in the diagnostics industry, bringing together innovative, complementary products, solutions, and services th…

Ortho Clinical Diagnostics lands CE mark for high-volume COVID-19 test

Ortho Clinical Diagnostics (NSDQ:OCDX) announced that it received a CE mark for its Vitros SARS-CoV-2 antigen test for COVID-19.

European approval follows the Vitros test’s initial launch in October 2020. The CE mark allows for more convenient sample collection and expanded viral transport media, according to a news release.

Personnel at hospitals, labs and other settings will now be able to use a nasal sample for the test rather than a nasopharyngeal swab specimen. Additionally, labs can now utilize three more viral transport media (VTM) options to expand options and testing capacity.

“Regions across the world are in various stages of reopening and recovering, yet there remains a great need for reliable tests that can be performed quickly and in bulk to ensure the continued safety of these ‘back-to-normal’ measures,” Ortho Clinical Diagnostics chief innovation officer Chockalingam Palaniappan said in the release. “Ort…

Ortho Clinical Diagnostics wins nearly $53.7M BARDA contract for COVID-19 tests

Ortho Clinical Diagnostics (NSDQ:OCDX) announced that it received a $53.7 million government contract for its COVID-19 tests.

Raritan, N.J.–based Ortho Clinical Diagnostics was awarded an undefinitized contract set to lead to a $53.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) as a continuation of the partnership between the two entities, according to a news release.

In September 2020, BARDA awarded Ortho Clinical Diagnostics nearly $12.9 million to support its COVID-19 antigen test development.

The latest BARDA contract is set to support a more than three-fold increase in domestic production capabilities for Ortho Clinical Diagnostics’ serological and diagnostic testing solutions, the company said.

Ortho Clinical Diagnostics is now set to receive enough funding to expand its capacity to provide up to 6.7 million COVID-19 tests per month for the U.S. market by the second quarter of 2022. The expan…

Ortho Clinical Diagnostics COVID-19 antibody tests wins CE mark

Ortho Clinical Diagnostics (NSDQ:OCDX) announced today that its new Vitros SARS-CoV-2 antibody assays received CE Mark approval.

Raritan, N.J.-based Ortho Clinical Diagnostics’ Vitros anti-SARS-CoV-2 total 2 antibody assay and the Vitros anti-SARS-CoV-2 IgG 2 antibody assay both received European approval for the qualitative and semi-quantitative detection of COVID-19 antibodies, according to a news release.

Both antibody assays generate a positive or negative result while also offering a measurement value for SARS-CoV-2 antibodies with easy-to-read results that are designed to eliminate the need for repeat testing and improve lab workflow. They can also be used to assess titers of neutralizing antibodies that generate the protective immune response and they can identify plasma suitable for convalescent plasma therapy.

The assays run on Ortho’s high-throughput, fully-automated analyzers, including the Vitros XT 7600 integrated system, the Vit…

AdvaMed unveils COVID-19 diagnostic supply registry

AdvaMed announced today that it created a comprehensive national COVID-19 diagnostic supply registry to aid state and federal pandemic responses.

According to a news release, AdvaMed is launching the registry in partnership with 13 commercial diagnostics manufacturers: Abbott (NYSE:ABT), Becton Dickinson (NYSE:BDX), bioMérieux, Bio-Rad Laboratories (NYSE:BIO), Beckman Coulter, Cepheid, Hologic (NSDQ:HOLX), Ortho Clinical Diagnostics, Qiagen (NYSE:QGEN), Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers (ETR: SHL), and Thermo Fisher Scientific (NYSE:TMO).

The AdvaMed registry is designed to compile information from the diagnostic companies, along with public data, to create a centralized and standardized COVID-19 diagnostic supply registry to update on weekly numbers at state and national levels regarding molecular, antigen and serology tests shipped in the U.S.

AdvaMed said in the release that the registry will also help streamline communicati…